deltatrials
Completed PHASE2 NCT00265655

Satraplatin for Patients With Metastatic Breast Cancer (MBC)

Phase II of Oral Satraplatin in Patients With Metastatic Breast Cancer (MBC)

Sponsor: Agennix

Conditions Metastatic Breast Cancer
Interventions Satraplatin
Updated 7 times since 2017 Last updated: Mar 22, 2012 Started: Nov 30, 2005 Primary completion: Jan 31, 2008 Completion: Feb 29, 2008

Listed as NCT00265655, this PHASE2 trial focuses on Metastatic Breast Cancer and remains completed. Sponsored by Agennix, it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Agennix
Data source: Agennix

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Dallas, United States